X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
MK-3543 (bomedemstat) is an investigational orally available small molecule that inhibits LSD1. It is under phase 3 clinical development for the treatment of essential thrombocythemia.
Lead Product(s): Bomedemstat
Therapeutic Area: Oncology Product Name: MK-3543
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2023
Details:
Under the acquisition agreement, Merck will strengthens the presence in the growing field of hematology by also acquiring pipeline of Imago, having lead candidate IMG-7289 (bomedemstat), an investigational orally available lysine-specific demethylase 1 (LSD1) inhibitor.
Lead Product(s): Bomedemstat
Therapeutic Area: Oncology Product Name: IMG-7289
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck Group
Deal Size: $1,350.0 million Upfront Cash: $1,350.0 million
Deal Type: Acquisition January 11, 2023
Details:
Phase 2 study of IMG-7289 (bomedemstat), an investigational oral lysine-specific demethylase 1 (LSD1) inhibitor, in combination with ruxolitinib (Jakafi®) in people with myelofibrosis (MF) conducted at the Department of Medicine, Queen Mary Hospital.
Lead Product(s): Bomedemstat,Ruxolitinib Phosphate
Therapeutic Area: Oncology Product Name: IMG-7289
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2022
Details:
IMG-7289 (bomedemstat), an investigational oral lysine-specific demethylase 1 (LSD1) inhibitor, has been generally well-tolerated and has demonstrated significant symptom improvement for patients with myelofibrosis and essential thrombocythemia.
Lead Product(s): Bomedemstat,Venetoclax
Therapeutic Area: Oncology Product Name: IMG-7289
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2022
Details:
Under the acquisition agreement, Merck will strengthens the presence in the growing field of hematology by also acquiring pipeline of Imago, having lead candidate bomedemstat (IMG-7289), an investigational orally available lysine-specific demethylase 1 (LSD1) inhibitor.
Lead Product(s): Bomedemstat
Therapeutic Area: Oncology Product Name: IMG-7289
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: $1,350.0 million Upfront Cash: $1,350.0 million
Deal Type: Acquisition November 21, 2022
Details:
IMG-7289 (bomedemstat, an orally available, small molecule inhibitor of LSD1, is the lead product candidate discovered by Imago for the treatment of certain myeloproliferative neoplasms (MPNs), a family of related, chronic cancers of the bone marrow.
Lead Product(s): Bomedemstat
Therapeutic Area: Oncology Product Name: IMG-7289
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2022
Details:
As of the data cutoff of, IMG-7289 (bomedemstat) demonstrated durability of response with 81% of patients achieving normalized platelet counts for at least 12 weeks.
Lead Product(s): Bomedemstat
Therapeutic Area: Oncology Product Name: IMG-7289
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2022
Details:
IMG-7289 (bomedemstat), an orally available, small molecule inhibitor of LSD1, is the lead product candidate discovered by Imago for the treatment of certain myeloproliferative neoplasms (MPNs), a family of related, chronic cancers of the bone marrow.
Lead Product(s): Bomedemstat
Therapeutic Area: Oncology Product Name: IMG-7289
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2022
Details:
A combination of IMG-7289 (bomedemstat), in solid tumors enhances their immunogenicity, and atezolizumab, a checkpoint inhibitor, represents in lung cancer treatment, may provide long-term disease management possibilities for patients with small cell lung cancer.
Lead Product(s): Bomedemstat,Atezolizumab
Therapeutic Area: Oncology Product Name: IMG-7289
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Washington University School of Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2022
Details:
IMG-7289 (bomedemstat) is an orally available LSD1 inhibitor, reduced elevated peripheral cell counts, spleen size, inflammatory cytokines, mutant allele frequencies, and marrow fibrosis.
Lead Product(s): Bomedemstat
Therapeutic Area: Oncology Product Name: IMG-7289
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2022
Details:
IMG-7289 (Bomedemstat), demonstrated durable clinical improvement in patients with ET who failed at least one standard therapy (usually hydroxyurea) and it is generally well-tolerated.
Lead Product(s): Bomedemstat
Therapeutic Area: Oncology Product Name: IMG-7289
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2021
Details:
Bomedemstat, an orally available, small molecule inhibitor of LSD1, is the lead product candidate discovered by Imago for the treatment of certain myeloproliferative neoplasms (MPNs), a family of related, chronic cancers of the bone marrow.
Lead Product(s): Bomedemstat
Therapeutic Area: Oncology Product Name: IMG-7289
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 30, 2021
Details:
The presented data show that bomedemstat was generally well-tolerated by patients with ET and demonstrated encouraging clinical activity as a monotherapy, showing symptomatic improvement in patients with significant MPN symptoms.
Lead Product(s): Bomedemstat
Therapeutic Area: Hematology Product Name: IMG-7289
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 11, 2021
Details:
Imago is evaluating Bomedemstat as a potentially disease-modifying therapy in two Phase 2 clinical trials for the treatment essential thrombocythemia (ET) and myelofibrosis (MF).
Lead Product(s): Bomedemstat
Therapeutic Area: Hematology Product Name: IMG-7289
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 21, 2021
Details:
Data presented at the 25th European Hematology Association (EHA) Annual Congress in June demonstrated that the Bomedemstat (first-in-class LSD1 inhibitor) was well tolerated with no dose-limiting toxicities or safety signals.
Lead Product(s): Bomedemstat
Therapeutic Area: Oncology Product Name: IMG-7289
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2020
Details:
Imago will use the proceeds to complete a Phase 3 study of bomedemstat for the treatment of myeloproliferative neoplasms. Bomedemstat (IMG-7289) is an orally available small molecule that inhibits lysine-specific demethylase 1 (LSD1).
Lead Product(s): Bomedemstat
Therapeutic Area: Oncology Product Name: IMG-7289
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Farallon Capital Management
Deal Size: $80.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing November 19, 2020
Details:
Interim data from its ongoing Phase 2b study evaluating bomedemstat (IMG-7289) for the treatment of myelofibrosis will be presented in an oral session during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition.
Lead Product(s): Bomedemstat
Therapeutic Area: Oncology Product Name: IMG-7289
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 05, 2020
Details:
The Phase 2b multi-center, open-label study is designed to assess the safety, efficacy, and pharmacodynamics of bomedemstat, an oral inhibitor of the epigenetic enzyme lysine-specific demethylase 1 (LSD1).
Lead Product(s): Bomedemstat
Therapeutic Area: Oncology Product Name: IMG-7289
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 01, 2020
Details:
EMA granted access to Imago's PRIME scheme for IMG-7289 (bomedemstat), a lysine-specific demethylase-1 inhibitor, for the treatment of intermediate-2 and high-risk patients with myelofibrosis who have become intolerant of, resistant to, or are ineligible for a JAK inhibitor.
Lead Product(s): Bomedemstat
Therapeutic Area: Oncology Product Name: IMG-7289
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 30, 2020
Details:
Treatment with Bomedemstat resulted in spleen volume and Total Symptom Score reductions in majority of the patients . Improvements were observed in anemia, bone marrow fibrosis and blast counts.
Lead Product(s): Bomedemstat
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
